And I will only be buying more on a value basis. Its sad, but...

And I will only be buying more on a value basis. Its sad, but many on here seem of the opinion a deal does not come without FDA approval and combined with a multitude of poor progress moments in the business since the dreaded Arpil 2023 rambiguous results, its dwindled to its 7 year lows again. It ain;t going to be a Golden Goose, its going to be a Phoenix from the ashes. if a partneship not announced before then.

Unless Paul does announce a partnership within his own recently described timeframes, the share price will indeed be going lower before EOFY. And with no shorts, investors have to look at their peers (or increasing absence of on here) as the part culprits in sellling shares (you have to go back to 2017 the last time it traded these levels (on an adjusted basis after heady $4+ highs in the silliness of early 2020 just before COVID hit).

PAR's prospects looked no better in 2020 of course, but there are a lot more shares on the registry now of course, as @Dungiven duely notes. More to come unless you get that MPS deal you have been alluding to for so long Paul?

I am more buying call options here than shares. Unless PR announces his deal they will continue to deacy into EOFY. If he does, they will surely explode like handgrenades on the news, so downtrodden are the shares of PAR. The prevalence of OA is well known. But talking of options, I'd say the mkt/pricing is only putting a 10% chance at best of PAR of getting to market and being a credible player.

Commiserations to buyers in 2020 through 2023 and those longer-term who did not sell some at least.